619:
594:
629:
526:
505:
353:
219:
693:
268:
250:
605:
21:
278:
181:
604:
371:
474:
31:
175:
576:
72:
808:
566:
330:
107:
823:
793:
677:
324:
410:
397:
683:
813:
542:
803:
113:
798:
300:
404:
828:
761:
This article should not be speedily deleted for lack of asserted importance because... (Ovation developed the anti-epileptic drug vigabatrin
533:
510:
818:
788:
384:
58:
742:
196:
291:
255:
127:
163:
132:
48:
643:
599:
102:
378:
365:
230:
465:
391:
93:
157:
27:
153:
701:
137:
653:
203:
417:
236:
746:
52:
739:
Desoxyn is not a brandname for dextroamphetamone - it is a brandname for methylamphetamine/methamphetamine
218:
437:
83:
770:
541:
on
Knowledge (XXG). If you would like to participate, please visit the project page, where you can join
299:
on
Knowledge (XXG). If you would like to participate, please visit the project page, where you can join
98:
169:
20:
765:. I will expand this information to the article and update it later today or possibly tomorrow) --
189:
79:
713:
705:
430:
766:
423:
283:
618:
593:
454:
634:
352:
782:
525:
504:
774:
750:
538:
692:
624:
273:
763:, as well as tetrabenazine, the only approved drug for Huntington's Disease
649:
296:
267:
249:
372:
Knowledge (XXG):Requested articles/Business and economics/Companies
716:. Please ensure the assessment is correct before removing the
212:
43:
15:
691:
648:, which aims to improve all articles or pages related to
188:
537:, a collaborative effort to improve the coverage of
295:, a collaborative effort to improve the coverage of
202:
682:This article has not yet received a rating on the
329:This article has not yet received a rating on the
61:for general discussion of the article's subject.
8:
411:Category:Company articles needing infoboxes
398:Category:Company articles needing attention
588:
499:
360:Here are some tasks awaiting attention:
338:
244:
216:
551:Knowledge (XXG):WikiProject Pharmacology
590:
501:
246:
717:
436:Help expand stub articles located at
309:Knowledge (XXG):WikiProject Companies
7:
809:Mid-importance pharmacology articles
640:This article is within the scope of
531:This article is within the scope of
385:Category:Unassessed company articles
289:This article is within the scope of
824:Unknown-importance Chicago articles
794:Unknown-importance company articles
662:Knowledge (XXG):WikiProject Chicago
235:It is of interest to the following
51:for discussing improvements to the
14:
814:WikiProject Pharmacology articles
554:Template:WikiProject Pharmacology
78:New to Knowledge (XXG)? Welcome!
804:Stub-Class pharmacology articles
627:
617:
603:
592:
524:
503:
462:Tag company talk pages with the
351:
276:
266:
248:
217:
73:Click here to start a new topic.
19:
571:This article has been rated as
30:on 22 June 2016. The result of
26:This article was nominated for
799:WikiProject Companies articles
451:Tag company articles with the
312:Template:WikiProject Companies
1:
751:13:09, 23 December 2009 (UTC)
545:and see a list of open tasks.
303:and see a list of open tasks.
70:Put new text under old text.
829:WikiProject Chicago articles
665:Template:WikiProject Chicago
342:WikiProject Companies To-do:
819:Stub-Class Chicago articles
789:Stub-Class company articles
845:
684:project's importance scale
577:project's importance scale
331:project's importance scale
775:15:40, 19 June 2014 (UTC)
699:
681:
654:Chicago metropolitan area
612:
570:
519:
337:
328:
261:
243:
108:Be welcoming to newcomers
534:WikiProject Pharmacology
53:Ovation Pharmaceuticals
700:This article has been
696:
438:Category:Company stubs
225:This article is rated
103:avoid personal attacks
695:
557:pharmacology articles
475:requests for comments
466:WikiProject Companies
292:WikiProject Companies
229:on Knowledge (XXG)'s
128:Neutral point of view
133:No original research
702:automatically rated
644:WikiProject Chicago
764:
757:Contested deletion
712:because it uses a
697:
231:content assessment
114:dispute resolution
75:
762:
732:
731:
728:
727:
724:
723:
708:or other tool as
587:
586:
583:
582:
498:
497:
494:
493:
490:
489:
486:
485:
211:
210:
94:Assume good faith
71:
42:
41:
836:
719:
670:
669:
668:Chicago articles
666:
663:
660:
637:
632:
631:
630:
621:
614:
613:
608:
607:
606:
596:
589:
559:
558:
555:
552:
549:
528:
521:
520:
515:
507:
500:
469:
458:
424:Portal:Companies
366:Article requests
355:
348:
347:
339:
317:
316:
315:company articles
313:
310:
307:
286:
284:Companies portal
281:
280:
279:
270:
263:
262:
252:
245:
228:
222:
221:
213:
207:
206:
192:
123:Article policies
44:
23:
16:
844:
843:
839:
838:
837:
835:
834:
833:
779:
778:
759:
737:
667:
664:
661:
658:
657:
633:
628:
626:
602:
556:
553:
550:
547:
546:
513:
482:
479:
463:
452:
314:
311:
308:
305:
304:
282:
277:
275:
226:
149:
144:
143:
142:
119:
89:
12:
11:
5:
842:
840:
832:
831:
826:
821:
816:
811:
806:
801:
796:
791:
781:
780:
758:
755:
736:
733:
730:
729:
726:
725:
722:
721:
698:
688:
687:
680:
674:
673:
671:
639:
638:
635:Chicago portal
622:
610:
609:
597:
585:
584:
581:
580:
573:Mid-importance
569:
563:
562:
560:
543:the discussion
529:
517:
516:
514:Mid‑importance
508:
496:
495:
492:
491:
488:
487:
484:
483:
481:
480:
478:
477:
471:
470:project banner
460:
448:
440:
426:
413:
400:
387:
374:
359:
357:
356:
344:
343:
335:
334:
327:
321:
320:
318:
301:the discussion
288:
287:
271:
259:
258:
253:
241:
240:
234:
223:
209:
208:
146:
145:
141:
140:
135:
130:
121:
120:
118:
117:
110:
105:
96:
90:
88:
87:
76:
67:
66:
63:
62:
56:
40:
39:
32:the discussion
24:
13:
10:
9:
6:
4:
3:
2:
841:
830:
827:
825:
822:
820:
817:
815:
812:
810:
807:
805:
802:
800:
797:
795:
792:
790:
787:
786:
784:
777:
776:
772:
768:
756:
754:
752:
748:
744:
743:121.209.48.46
740:
734:
715:
714:stub template
711:
707:
703:
694:
690:
689:
685:
679:
676:
675:
672:
655:
651:
647:
646:
645:
636:
625:
623:
620:
616:
615:
611:
601:
598:
595:
591:
578:
574:
568:
565:
564:
561:
544:
540:
536:
535:
530:
527:
523:
522:
518:
512:
509:
506:
502:
476:
472:
467:
461:
456:
450:
449:
447:
445:
441:
439:
435:
433:
432:
427:
425:
422:
420:
419:
414:
412:
409:
407:
406:
401:
399:
396:
394:
393:
388:
386:
383:
381:
380:
375:
373:
370:
368:
367:
362:
361:
358:
354:
350:
349:
346:
345:
341:
340:
336:
332:
326:
323:
322:
319:
302:
298:
294:
293:
285:
274:
272:
269:
265:
264:
260:
257:
254:
251:
247:
242:
238:
232:
224:
220:
215:
214:
205:
201:
198:
195:
191:
187:
183:
180:
177:
174:
171:
168:
165:
162:
159:
155:
152:
151:Find sources:
148:
147:
139:
138:Verifiability
136:
134:
131:
129:
126:
125:
124:
115:
111:
109:
106:
104:
100:
97:
95:
92:
91:
85:
81:
80:Learn to edit
77:
74:
69:
68:
65:
64:
60:
54:
50:
46:
45:
37:
33:
29:
25:
22:
18:
17:
760:
741:
738:
709:
642:
641:
572:
548:Pharmacology
539:Pharmacology
532:
511:Pharmacology
457:|Companies}}
443:
442:
429:
428:
416:
415:
403:
402:
390:
389:
377:
376:
364:
363:
290:
237:WikiProjects
199:
193:
185:
178:
172:
166:
160:
150:
122:
47:This is the
36:no consensus
35:
767:Formerly 98
176:free images
59:not a forum
783:Categories
720:parameter.
710:Stub-class
227:Stub-class
753:Jonathan
306:Companies
297:companies
256:Companies
116:if needed
99:Be polite
49:talk page
459:template
418:Maintain
392:Copyedit
84:get help
57:This is
55:article.
28:deletion
659:Chicago
652:or the
650:Chicago
600:Chicago
575:on the
473:Answer
405:Infobox
182:WP refs
170:scholar
718:|auto=
455:portal
379:Assess
233:scale.
154:Google
735:Notes
704:by a
444:Other
431:Stubs
197:JSTOR
158:books
112:Seek
771:talk
747:talk
190:FENS
164:news
101:and
34:was
706:bot
678:???
567:Mid
325:???
204:TWL
785::
773:)
749:)
468:}}
464:{{
453:{{
184:)
82:;
769:(
745:(
686:.
656:.
579:.
446::
434::
421::
408::
395::
382::
369::
333:.
239::
200:·
194:·
186:·
179:·
173:·
167:·
161:·
156:(
86:.
38:.
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
